126 related articles for article (PubMed ID: 20428831)
41. Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma.
Yasuda M; Ogane N; Hayashi H; Kameda Y; Miyagi Y; Iida T; Mori Y; Tsukinoki K; Minematsu T; Osamura Y
Oncol Rep; 2005 Dec; 14(6):1499-504. PubMed ID: 16273245
[TBL] [Abstract][Full Text] [Related]
42. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X
Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928
[TBL] [Abstract][Full Text] [Related]
43. Tie-2 and angiopoietin-1 expression in human thyroid tumors.
Mitsutake N; Namba H; Takahara K; Ishigaki K; Ishigaki J; Ayabe H; Yamashita S
Thyroid; 2002 Feb; 12(2):95-9. PubMed ID: 11916292
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
45. The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas.
Zeng Q; Chen G; Vlantis A; Tse G; van Hasselt C
J Pathol; 2008 Mar; 214(4):425-33. PubMed ID: 18085520
[TBL] [Abstract][Full Text] [Related]
46. [The significance of p63 expression in thyroid neoplasm].
Qian M; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Oct; 22(19):888-90, 893. PubMed ID: 19160863
[TBL] [Abstract][Full Text] [Related]
47. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
48. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
[TBL] [Abstract][Full Text] [Related]
49. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
50. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O
Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501
[TBL] [Abstract][Full Text] [Related]
52. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma.
Cheng SP; Liu CL; Hsu YC; Chang YC; Huang SY; Lee JJ
Cell Biochem Biophys; 2013 Mar; 65(2):203-10. PubMed ID: 22907586
[TBL] [Abstract][Full Text] [Related]
53. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer.
Wang S; Lloyd RV; Hutzler MJ; Safran MS; Patwardhan NA; Khan A
Mod Pathol; 2000 Aug; 13(8):882-7. PubMed ID: 10955455
[TBL] [Abstract][Full Text] [Related]
54. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.
Wojtas B; Ferraz C; Stokowy T; Hauptmann S; Lange D; Dralle H; Musholt T; Jarzab B; Paschke R; Eszlinger M
Mol Cell Endocrinol; 2014 May; 388(1-2):1-9. PubMed ID: 24631480
[TBL] [Abstract][Full Text] [Related]
55. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.
Kogai T; Hershman JM; Motomura K; Endo T; Onaya T; Brent GA
Endocrinology; 2001 Aug; 142(8):3369-79. PubMed ID: 11459780
[TBL] [Abstract][Full Text] [Related]
56. Expression of S100A2 and S100A6 in thyroid carcinomas.
Ito Y; Yoshida H; Tomoda C; Uruno T; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Histopathology; 2005 May; 46(5):569-75. PubMed ID: 15842639
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
58. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma.
Miettinen M; Franssila KO
Hum Pathol; 2000 Sep; 31(9):1139-45. PubMed ID: 11014583
[TBL] [Abstract][Full Text] [Related]
59. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.
Varinelli L; Caccia D; Volpi CC; Caccia C; De Bortoli M; Taverna E; Gualeni AV; Leoni V; Gloghini A; Manenti G; Bongarzone I
Endocr Relat Cancer; 2015 Oct; 22(5):759-75. PubMed ID: 26206776
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
